Oct 29 (Reuters) - Correvio Pharma Corp CORV.TO :
* CORREVIO ANNOUNCES BRINAVESS ELIGIBILITY FOR PATENT EXTENSION
* CORREVIO PHARMA - RECEIVED INDEPENDENT REGULATORY AND LEGAL OPINIONS THAT BRINAVESS MAY QUALIFY FOR UP TO 5-YEAR PATENT EXTENSION FROM USPTO
* CORREVIO PHARMA CORP - WILL BE RESUBMITTING A NEW DRUG APPLICATION (NDA) FOR BRINAVESS TO FDA DURING Q2 OF 2019